Tourette Syndrome Therapeutic and Drug Pipeline Review H2 adds “Tourette Syndrome - Pipeline Review, H1 2016” reports to its database.

Get Sample Report @

The report provides comprehensive information on the therapeutics under development for Tourette Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

- The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome
- The report reviews pipeline therapeutics for Tourette Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Tourette Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Tourette Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Tourette Syndrome

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Tourette Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tourette Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Tourette Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Tourette Syndrome - Overview 8
Tourette Syndrome - Therapeutics under Development by Companies 9
Tourette Syndrome - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Tourette Syndrome - Products under Development by Companies 13
Tourette Syndrome - Companies Involved in Therapeutics Development 14
Catalyst Pharmaceutical Partners, Inc. 14
Edison Pharmaceuticals, Inc. 15
Neurocrine Biosciences, Inc. 16
Psyadon Pharmaceuticals, Inc. 17
Reviva Pharmaceuticals Inc. 18
Synchroneuron Inc. 19
Teva Pharmaceutical Industries Limited 20
Therapix Biosciences Ltd 21
Tourette Syndrome - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23

Access Report @

Get in touch:

Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseGuy Reports
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349

Release ID: 149539